Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer

Summary

Open-label, randomized, active-controlled, two-arm Phase III study to compare the efficacy and safety of AEZS-108 and doxorubicin.

Timeline

Start

2013-04

Primary completion

2017-01-30

Completion

2017-01-30

Publications

• Mathews C, Lorusso D, Coleman RL, Boklage S, Garside J. An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer. Oncologist. 2022 Dec 9;27(12):1058-1066. doi: 10.1093/oncolo/oyac188.

Drugs

Indications